38 results on '"Lassalle, Régis"'
Search Results
2. COVID-19 and pregnancy: A European study on pre- and post-infection medication use.
- Author
-
Hurley, Eimir, Geisler, Benjamin P., Lupattelli, Angela, Poblador-Plou, Beatriz, Lassalle, Régis, Jové, Jérémy, Bernard, Marie-Agnes, Sakr, Dunia, Sanfélix-Gimeno, Gabriel, Sánchez-Saez, Francisco, Rodríguez-Bernal, Clara L., Sabaté, Mònica, Ballarín, Elena, Aguilera, Cristina, Jordan, Sue, Thayer, Daniel, Farr, Ian, Ahmed, Saira, Bartolini, Claudia, and Limoncella, Giorgio
- Subjects
- *
ANTIBIOTICS , *STEROID drugs , *PREGNANCY , *RESEARCH funding , *SCIENTIFIC observation , *INFECTION , *PREGNANT women , *FIBRINOLYTIC agents , *PRE-tests & post-tests , *ANTIVIRAL agents , *DURATION of pregnancy , *ELECTRONIC health records , *COVID-19 , *DRUG utilization - Abstract
Purpose: The COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19, focusing on variations by trimester of infection and location. Methods: We conducted an observational study using six electronic healthcare databases from six European regions (Aragon/Spain; France; Norway; Tuscany, Italy; Valencia/Spain; and Wales/UK). The prevalence of primary care prescribing or dispensing was compared in the 30-day periods before and after a positive COVID-19 test or diagnosis. Results: The study included 294,126 pregnant women, of whom 8943 (3.0%) tested positive for, or were diagnosed with, COVID-19 during their pregnancy. A significantly higher use of antithrombotic medications was observed particularly after COVID-19 infection in the second and third trimesters. The highest increase was observed in the Valencia region where use of antithrombotic medications in the third trimester increased from 3.8% before COVID-19 to 61.9% after the infection. Increases in other countries were lower; for example, in Norway, the prevalence of antithrombotic medication use changed from around 1–2% before to around 6% after COVID-19 in the third trimester. Smaller and less consistent increases were observed in the use of other drug classes, such as antimicrobials and systemic corticosteroids. Conclusion: Our findings highlight the substantial impact of COVID-19 on primary care medication use among pregnant women, with a marked increase in the use of antithrombotic medications post-COVID-19. These results underscore the need for further research to understand the broader implications of these patterns on maternal and neonatal/fetal health outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Analgesic switching in chronic users of dextropropoxyphene in France.
- Author
-
Daveluy, Amélie, Bryan, Michael Charles, Miremont‐Salamé, Ghada, Lassalle, Régis, Lacueille, Clémentine, Grelaud, Angela, Floccia, Marie, Haramburu, Françoise, Lapeyre‐Mestre, Maryse, Micallef, Joëlle, and Salvo, Francesco
- Subjects
- *
OPIOID analgesics , *ANALGESICS , *DATABASES , *OPIOIDS , *DRUG utilization , *ACETAMINOPHEN , *CROSS-sectional method - Abstract
Background: The combination dextropropoxyphene/paracetamol (DXP/P) was the most prescribed opioid analgesic until its withdrawal in 2011. Objectives: This study investigated dispensations of analgesics in chronic users of DXP/P during the 18 months following its withdrawal. Methods: A cross‐sectional study repeated yearly was conducted by using the French reimbursement database from 2006 to 2015. Chronic DXP/P users were defined as patients who received at least 40 boxes of DXP/P in the year prior to withdrawal. Data on analgesic dispensing were analyzed at DXP/P withdrawal (T0) and then every 6 months for 18 months. Results: A total of 63 671 subjects had a DXP/P reimbursement in the year prior to its discontinuation, of whom 7.1% were identified as chronic users (mean age: 71.5 years, women: 68.7%). Among the patients taking DXP/P alone at T0 (74.6%), one fourth switched to a peripheral analgesic, one fourth to a combination of peripheral analgesic/opioid, one fourth to another opioid, and the others mainly discontinued their treatment (14.1%) or died. During the following 12 months, most of the subjects taking only peripheral analgesics continued this treatment, while half of the subjects with a combination of opioid/peripheral analgesic or taking only an analgesic remained on this type of treatment. Conclusion: Eighteen months after DXP/P withdrawal, more than 10% of patients stopped taking an analgesic. Vigilance is required regarding any change in analgesics by regularly reassessing patients' pain and, in the case of opioid treatments, by monitoring the risk of use disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database.
- Author
-
Blin, Patrick, Joubert, Michael, Jourdain, Patrick, Zaoui, Philippe, Guiard, Estelle, Sakr, Dunia, Dureau-Pournin, Caroline, Bernard, Marie-Agnès, Lassalle, Régis, Thomas-Delecourt, Florence, Bineau, Sébastien, Moore, Nicholas, and Droz-Perroteau, Cécile
- Subjects
- *
TYPE 2 diabetes , *CARDIOVASCULAR diseases , *KIDNEY diseases , *HEART failure , *PEOPLE with diabetes , *DATABASES - Abstract
Background: Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes. The objective was to estimate the incidence of the first occurring CVRD manifestation and cumulative hospitalization costs of each CVRD manifestation for type 2 diabetes without CVRD history. Methods: A cohort study of all type 2 diabetes free of CVRD as of January 1st 2014, was identified and followed-up for 5 years within the French SNDS nationwide claims database. The cumulative incidence of the first occurring CVRD manifestation was estimated using the cumulative incidence function, with death as a competing risk. Cumulative hospitalization costs of each CVRD manifestations were estimated from the perspective of all payers. Results: From 2,079,089 type 2 diabetes without cancer or transplantation, 76.5% were free of CVRD at baseline with a mean age of 65 years, 52% of women and 7% with microvascular complications history. The cumulative incidence of a first CVRD manifestation was 15.3% after 5 years of follow-up with a constant linear increase over time for all CVRD manifestations: The most frequent was CKD representing 40.6% of first occurred CVRD manifestation, followed by HF (23.0%), then PAD (13.5%), stroke (13.2%) and MI (9.7%). HF and CKD together reached about one patient out of ten after 5 years and represented 63.6% of first CVRD manifestations. The 5-year global cost of all CVRD hospitalizations was 3.9 billion euros (B€), i.e. 2,450€ per patient of the whole cohort, with an exponential increase over time for each specific CVRD manifestation. The costliest was CKD (2.0 B€), followed by HF (1.2 B€), then PAD (0.7 B€), stroke (0.6 B€) and MI (0.3 B€). Conclusions/interpretation: While MI, stroke and PAD remain classic major risks of complications for CVRD-free type 2 diabetes, HF and CKD nowadays represent individually a higher risk and cost than each of these classic manifestations, and jointly represents a risk and a cost twice as high as these three classic manifestations all together. This should encourage the development of specific HF and CKD preventive strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.
- Author
-
Blin, Patrick, Dureau-Pournin, Caroline, Lassalle, Régis, Jové, Jérémy, Thomas-Delecourt, Florence, Droz-Perroteau, Cécile, Danchin, Nicolas, and Moore, Nicholas
- Subjects
- *
PLATELET aggregation inhibitors , *MYOCARDIAL infarction , *ANTICOAGULANTS , *KIDNEY diseases , *STROKE , *PATIENTS , *THERAPEUTICS - Abstract
Aims The present study aims to describe real-life outcomes in stable patients after-myocardial infarction (MI) similar to those in the PEGASUS-TIMI 54 trial (PEGASUS), which found long-term benefits of ticagrelor in patients with a history of MI. Methods One-year event-free post-MI patients were identified in the French claims database representative 1/97 sample (2005-2010) and followed for up to 3 years. A PEGASUS-like (PL) population included patients with age ≥ 65 years, or age ≥ 50 and diabetes, renal dysfunction or prior MI, without stroke, end-stage renal failure or oral anticoagulation. Outcomes were: a composite of all-cause death or hospital admission for MI or stroke; individual events; major bleeding. Results There were 1585 post-MI patients totalling 3926 person-years including 865 PL patients (2114 PY); 68% were male; mean age was 66 (standard deviation 15) in post-MI, 74 (10) in PL. Outcomes per 100 person-years [95% confidence interval] were, respectively, in post-MI and PL 6.3 [5.6-7.1] and 7.8 [6.7-8.9] for the composite outcome; 5.1 [4.4-5.8] and 6.5 [5.5-7.6] for death; 1.0 [0.7-1.3] and 1.0 [0.6-1.4] for MI; 0.6 [0.4-0.9] and 0.9 [0.5-1.2] for stroke; 1.3 [0.9-1.6] and 1.4 [0.9-1.9] for major bleeding. Event rates were stable over the 3 study years. Placebo patients in the PEGASUS-TIMI54 Study were younger, more often male and had lower event rates, especially for all-cause death and major bleeding. Conclusions Patients selected using the criteria described in PEGASUS were older with more comorbidities, resulting in higher all-cause death and bleeding rates, but similar MI recurrence rates. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Drug use in French children: a population-based study.
- Author
-
Bénard-Laribière, Anne, Jové, Jérémy, Lassalle, Régis, Robinson, Philip, Droz-Perroteau, Cécile, and Noize, Pernelle
- Subjects
- *
CHILDREN & drugs , *CHILDREN , *OUTPATIENT medical care , *CROSS-sectional method , *NATIONAL health services , *ACETAMINOPHEN , *ANTI-infective agents , *ADRENOCORTICAL hormones , *DRUG utilization statistics , *DATABASES , *DISEASE prevalence ,DRUGS & economics - Abstract
Background and Objective: To provide an overview of drug use in outpatient children in France, a population-based study using a national reimbursement claims database representative of 90% of the French population was conducted.Design: Cross-sectional study performed between January and December 2011 using the EGB database (Echantillon Généraliste de Bénéficiaires), a 1/97th sample of the national healthcare insurance system beneficiaries. Drug use in children <18 years old was estimated through reimbursements for prescribed drugs excluding vaccines. Prevalences of use were calculated for different levels of the Anatomical Therapeutic Chemical classification by considering as users children who had at least one reimbursement during the study period.Results: In 2011, 133,800 children were included in the study. The overall prevalence of drug use was 84% and the median number of different drugs per child was 5. Drug use was greatest in children aged <2 years. The most widely used drugs were paracetamol, systemic anti-infectives, nasal corticosteroids and decongestants, and anti-histamines. 21% children <2 years received domperidone.Conclusions: There is widespread use of medicines that are unlikely to be effective and may have significant toxicity in French children. Irrational use of medicines appears to be greatest in children aged 5 years and under. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
7. Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
- Author
-
Bosco‐Lévy, Pauline, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Lignot, Séverine, Diez, Pauline, Abouelfath, Abdelilah, Lassalle, Régis, Blin, Patrick, and Droz‐Perroteau, Cécile
- Subjects
- *
DIMETHYL fumarate , *MULTIPLE sclerosis , *DISEASE relapse , *ODDS ratio , *LOGISTIC regression analysis , *NATALIZUMAB - Abstract
Aims: To assess the effectiveness of dimethyl fumarate (DMF) on annual rate of relapse subject to treatment (ARRt) and disability progression in multiple sclerosis (MS) compared to injectable immunomodulators (IMM), teriflunomide (TERI) and fingolimob (FTY), in real‐life setting. Methods: A population‐based cohort study was conducted using data of the French nationwide claims database, SNDS. All patients initiating IMM, TERI, FTY or DMF between 1 July 2015 and 12 December 2017, with 4.5 years of database history and 1–3.5 years of follow‐up were included in this study. DMF patients were 1:1 matched to IMM, TERI or FTY using a high dimensional propensity score. Negative binomial regression and a logistic regression model were used to estimate the relative risk (RR ± [95% CI]) of ARRt and the odds ratio (OR ± [95% CI]) of disability progression, respectively. Results: Overall, 9304 subjects were identified: 29.0% initiated DMF, 33.2% TERI, 5.6% FTY and 32.2% an IMM. The matched cohorts consisted of 1779 DMF‐IMM patients, 1679 DMF‐TERI patients, and 376 DMF‐FTY patients. DMF significantly reduced ARRt compared to IMM (RR 0.72 [0.61–0.86]) and TERI (0.81 [0.68–0.96]) and did not show any significant difference when compared with FTY. The risk of the progression of MS‐specific disability was not significantly different for any matched cohorts. Conclusion: DMF is associated with lower risk of treated relapse for patients with RRMS than other first‐line RRMS agents (TERI and IIM). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Patients with stable coronary artery disease and type 2 diabetes but without prior myocardial infarction or stroke and THEMIS-like patients: real-world prevalence and risk of major outcomes from the SNDS French nationwide claims database.
- Author
-
Blin, Patrick, Darmon, Patrice, Henry, Patrick, Guiard, Estelle, Bernard, Marie-Agnès, Dureau-Pournin, Caroline, Maizi, Hélène, Thomas-Delecourt, Florence, Lassalle, Régis, Droz-Perroteau, Cécile, and Moore, Nicholas
- Subjects
- *
CORONARY artery disease , *MYOCARDIAL infarction , *DRUG-eluting stents , *TYPE 2 diabetes , *STROKE patients , *ADULTS - Abstract
Aim and hypotheses: The THEMIS randomized trial compared ticagrelor plus aspirin versus placebo plus aspirin for patients with stable coronary artery disease and type 2 diabetes mellitus (CAD-T2DM), and without prior myocardial infarction (MI) or stroke. The aim of the study was to quantify the size of the CAD-T2DM population without prior MI or stroke population in a real-world setting, and more specifically populations with similar THEMIS selection criteria (THEMIS-like and THEMIS-PCI-like populations), as well as their risk of major outcomes in current practice. Methods: A 2-year follow-up cohort study included all CAD-T2DM without MI/stroke prevalent patients on January 1st, 2014 in the SNDS French nationwide claims database. The THEMIS-like population concerned those ≥ 50 years of age with similar THEMIS inclusion and exclusion criteria. Prevalence was standardized to the European population. The cumulative incidence function was used to estimate the incidence of clinical outcomes (MI, ischemic stroke, and major bleeding according to the TIMI classification) with death as competing risk, and the Kaplan–Meier estimate for all-cause death and a composite outcome of MI, stroke and all-cause death. Results: From a population of about 50 million adults, the prevalence of CAD-T2DM without MI/stroke, THEMIS-like and THEMIS-PCI-like populations was respectively at 6.04, 1.50 and 0.27 per 1000 adults, with a mean age of 72.7, 72.3 and 70.9 years and less comorbidities and diabetic complications for the THEMIS-like and THEMIS-PCI-like population. The 2-year cumulative incidence was respectively 1.7%, 1.3% and 1.6% for MI, 1.7%, 1.5% and 1.4% for stroke, 4.8%, 3.1% and 2.9% for major bleeding, 13.6%, 9.7% and 6.8% for all-cause death, and 16.2%, 12.0% and 9.5% for the composite outcome. Conclusion: THEMIS-like prevalence was estimated at 1.50 per 1,000 adults, representing about a quarter of CAD-T2DM without MI/stroke patients, and 0.27 per 1000 adults for the THEMIS-PCI-like populations. In current French practice, the median age of both these populations was about 5–6 years older than in the THEMIS trial, with a 2-year incidence of major outcomes between two or four time above the ones of the placebo arm of the THEMIS trial using very close definitions. Registration No. EUPAS27402 (http://www.ENCEPP.eu). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Nurses' internal contamination by antineoplastic drugs in hospital centers: a cross-sectional descriptive study.
- Author
-
Villa, Antoine, Molimard, Mathieu, Sakr, Dunia, Lassalle, Régis, Bignon, Emmanuelle, Martinez, Béatrice, Rouyer, Magali, Mathoulin-Pelissier, Simone, Baldi, Isabelle, Verdun-Esquer, Catherine, and Canal-Raffin, Mireille
- Subjects
- *
ANTINEOPLASTIC agents , *LIQUID chromatography-mass spectrometry , *HOSPITAL nursing staff , *NURSES , *CROSS-sectional method - Abstract
Objective: The aim of this study was to assess internal antineoplastic drugs (ADs) contamination in the nursing staff in French hospital centers, using highly sensitive analytical methods. Methods: This cross-sectional study included nurses practicing in care departments where at least one of the five ADs studied was handled (5-fluorouracil, cyclophosphamide, doxorubicin, ifosfamide, methotrexate). The nurses study participation lasted 24 h including collection of three urine samples and one self-questionnaire. All urine samples were assayed by ultra-high-performance liquid chromatography–tandem mass spectrometry methods with very low value of the lower limit of quantification (LLOQ). Results: 74 nurses were included, 222 urine samples and 74 self-questionnaires were collected; 1092 urine assays were performed. The percentage of nurses with internal AD contamination was 60.8% and low levels of urinary concentrations were measured. Regarding nurses with internal contamination (n = 45), 42.2% presented internal contamination by methotrexate, 37.8% by cyclophosphamide, 33.3% by ifosfamide, 17.8% by 5-fluorouracil metabolite and 6.7% by doxorubicine. Among the positive assays, 17.9% (n = 26/145) were not explained by exposure data from the self-questionnaire but this could be due to the skin contact of nurses with contaminated work surfaces. Conclusions: This study reported high percentage of nurses with internal ADs contamination. The low LLOQ values of the used analytical methods, allowed the detection of ADs that would not have been detected with the current published methods: the percentage of contamination would have been 17.6% instead of the 60.8% reported here. Pending toxicological reference values, urine ADs concentrations should be reduced as low as reasonably achievable (ALARA principle). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Are traditional NSAIDs prescribed appropriately among French elderly with osteoarthritis? Results from the CADEUS cohort.
- Author
-
Gulmez, Sinem, Droz-Perroteau, Cécile, Lassalle, Régis, Blin, Patrick, Bégaud, Bernard, Rossignol, Michel, Moore, Nicholas, and Fourrier-Réglat, Annie
- Subjects
- *
DRUG laws , *DRUG standards , *ANALYSIS of variance , *COMPUTER software , *DATABASES , *DRUG prescribing , *LONGITUDINAL method , *NONSTEROIDAL anti-inflammatory agents , *OSTEOARTHRITIS , *RESEARCH funding , *PHYSICIAN practice patterns , *DATA analysis , *SECONDARY analysis , *OLD age ,EVALUATION of drug utilization - Abstract
im: To describe the inappropriate use of traditional non-steroidal anti-inflammatory drugs (tNSAIDs) in elderly subjects in the CADEUS cohort using the Beers 2003 criteria modified by recommendations from the French Medicines Agency. Methods: Of the 23,217 subjects in the CADEUS cohort, 1,851 were ≥65 years old, had bee diagnosed with osteoarthritis (OA), and had been dispensed a tNSAID at least once in the 6 months before the index date. Data were obtained from the French national reimbursement database and from patient and prescriber questionnaires. The Beers criteria for inappropriate use were modified to include all tNSAIDs, and long-term high-dose use was defined as having been dispensed at least five dispensations for tNSAID over a 6-month period with a gap of <45 days between each dispensation and when the gap was >45 days, medicine availability >50% [i.e., defined daily dose (DDD) delivered/theoretical DDD] for the gap. Results: The most frequently dispensed tNSAIDs were piroxicam (25%), diclofenac (24%), ibuprofen (18%), ketoprofen (18%), and naproxen (10%). Of the study population, 1.5% were dispensed indomethacin; 15%, two tNSAIDs; 15%, a tNSAIDs with a platelet aggregation inhibitor; 4.6%, a tNSAID with low-dose aspirin; 0.2%, a tNSAID with vitamin K antagonists. The analysis revealed that 18% of the study population were high-dose and long-term users of tNSAIDs and that 70% of these were dispensed a proton pump inhibitor. Conclusions: The most common inappropriate tNSAID dispensation was the co-prescription of two different tNSAIDs within 1 month or of a platelet aggregation inhibitor. The real-life consequences of our results need to be ascertained, and it would be interesting to update the Beers criteria. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
11. Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data.
- Author
-
Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, and Maillart, Elisabeth
- Subjects
- *
ELECTRONIC health records , *CASTRATION-resistant prostate cancer , *ALGORITHMS , *MEDICAL care - Abstract
Background: Diagnosis performances of case-identifying algorithms developed in healthcare database are usually assessed by comparing identified cases with an external data source. When this is not feasible, intra-database validation can present an appropriate alternative.Objectives: To illustrate through two practical examples how to perform intra-database validations of case-identifying algorithms using reconstituted Electronic Health Records (rEHRs).Methods: Patients with 1) multiple sclerosis (MS) relapses and 2) metastatic castration-resistant prostate cancer (mCRPC) were identified in the French nationwide healthcare database (SNDS) using two case-identifying algorithms. A validation study was then conducted to estimate diagnostic performances of these algorithms through the calculation of their positive predictive value (PPV) and negative predictive value (NPV). To that end, anonymized rEHRs were generated based on the overall information captured in the SNDS over time (e.g. procedure, hospital stays, drug dispensing, medical visits) for a random selection of patients identified as cases or non-cases according to the predefined algorithms. For each disease, an independent validation committee reviewed the rEHRs of 100 cases and 100 non-cases in order to adjudicate on the status of the selected patients (true case/ true non-case), blinded with respect to the result of the corresponding algorithm.Results: Algorithm for relapses identification in MS showed a 95% PPV and 100% NPV. Algorithm for mCRPC identification showed a 97% PPV and 99% NPV.Conclusion: The use of rEHRs to conduct an intra-database validation appears to be a valuable tool to estimate the performances of a case-identifying algorithm and assess its validity, in the absence of alternative. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response.
- Author
-
Astrugue, Cyril, Bénard, Antoine, Bosco-Levy, Pauline, Dulucq, Stéphanie, Rouyer, Magali, Lassalle, Régis, Hayes, Nathalie, and Mahon, François-Xavier
- Subjects
- *
MARKOV chain Monte Carlo , *CHRONIC myeloid leukemia , *KINASE inhibitors , *MONTE Carlo method , *MEDICAL personnel , *MEDICAL care costs , *PROTEIN-tyrosine kinase inhibitors - Abstract
Objectives: Tyrosine kinase inhibitors (TKIs) account for the vast majority of healthcare expenditure on patients with chronic myeloid leukemia (CML), and it has been demonstrated that TKI discontinuation in patients in long-term deep molecular remission (DMR) is safe and improves quality of life. Our objective was to estimate the budget impact of TKI discontinuation in CML patients in long-term DMR from the perspective of the French healthcare system.Methods: This analysis was conducted over a 5-year time horizon using a Markov model with cycles of 6 months. Transition probabilities were estimated through systematic reviews and meta-analyses. Costs were estimated from the French National Claims Database. Monte Carlo simulations were performed to take into account the uncertainty surrounding model parameters. Sensitivity analyses were carried out by varying the size of the target population and the cost of TKIs.Results: Over a 5-year period and for a target population of 100 patients each year eligible and agreeing to stop TKI, the TKI discontinuation strategy would save €25.5 million (95% confidence interval -39.3 to 70.0). In this model, the probability that TKI discontinuation would be more expensive than TKI continuation was 12.0%. In sensitivity analyses, mean savings ranged from €14.9 million to €62.9 million.Conclusions: This study provides transparent, reproducible, and interpretable results for healthcare professionals and policy makers. Our results clearly show that innovative healthcare strategies can benefit both the healthcare system and patients. Savings from generalizing TKI discontinuation in CML patients in sustained DMR should yield health gains for other patients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data.
- Author
-
Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, and Maillart, Elisabeth
- Subjects
- *
ELECTRONIC health records , *CASTRATION-resistant prostate cancer , *ALGORITHMS , *MEDICAL care - Abstract
Background: Diagnosis performances of case-identifying algorithms developed in healthcare database are usually assessed by comparing identified cases with an external data source. When this is not feasible, intra-database validation can present an appropriate alternative. Objectives: To illustrate through two practical examples how to perform intra-database validations of case-identifying algorithms using reconstituted Electronic Health Records (rEHRs). Methods: Patients with 1) multiple sclerosis (MS) relapses and 2) metastatic castration-resistant prostate cancer (mCRPC) were identified in the French nationwide healthcare database (SNDS) using two case-identifying algorithms. A validation study was then conducted to estimate diagnostic performances of these algorithms through the calculation of their positive predictive value (PPV) and negative predictive value (NPV). To that end, anonymized rEHRs were generated based on the overall information captured in the SNDS over time (e.g. procedure, hospital stays, drug dispensing, medical visits) for a random selection of patients identified as cases or non-cases according to the predefined algorithms. For each disease, an independent validation committee reviewed the rEHRs of 100 cases and 100 non-cases in order to adjudicate on the status of the selected patients (true case/ true non-case), blinded with respect to the result of the corresponding algorithm. Results: Algorithm for relapses identification in MS showed a 95% PPV and 100% NPV. Algorithm for mCRPC identification showed a 97% PPV and 99% NPV. Conclusion: The use of rEHRs to conduct an intra-database validation appears to be a valuable tool to estimate the performances of a case-identifying algorithm and assess its validity, in the absence of alternative. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Effectiveness of first‐line cetuximab in wild‐type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort.
- Author
-
Rouyer, Magali, François, Eric, Sa Cunha, Antonio, Monnereau, Alain, Bignon, Emmanuelle, Jové, Jérémy, Lassalle, Régis, Droz‐Perroteau, Cécile, Moore, Nicholas, Noize, Pernelle, Fourrier‐Réglat, Annie, and Smith, Denis
- Subjects
- *
CETUXIMAB , *HOSPITAL central service departments , *BRAF genes , *METASTASIS , *MOLECULAR genetics , *PROGRESSION-free survival , *GENDER - Abstract
Aims: Poor efficacy has been reported for patients with BRAF mutations for metastatic colorectal cancer (mCRC). Methods: EREBUS is a French cohort study of wild‐type (wt) KRAS unresectable mCRC patients initiating a first‐line treatment with cetuximab from 2009 to 2010, followed for two years (five years for vital status). Molecular genetics platforms have provided additional RAS and BRAF mutation testing results. Progression‐free survival (PFS) and overall survival (OS) were assessed according to tumour mutation (mt) status: RASmt/BRAFany, RASwt/BRAFmt and RASwt/BRAFwt. Multivariate Cox analyses were used to evaluate association between mutation status and death or progression. Results: A total of 389 patients were included in 65 centres and with a known tumour mutation status: 64 RASmt/BRAFany (21%), 33 RASwt/BRAFmt (13%) and 213 RASwt/BRAFwt (87%). Respective baseline characteristics were: median age 65, 64 and 63 years, male gender 63%, 64% and 69%, Eastern Cooperative Oncology Group performance status ≤ 1 75%, 76% and 79%, and liver‐only metastases 39%, 33% and 40%. Median progression‐free survival was 8.0 months [5.9–9.3] for patients with RASmt/BRAFany, 6.0 months [2.3–7.2] for patients with RASwt/BRAFmt, and 10.4 months [9.5–11.0] for patients with RASwt/BRAFwt. Respectively, median overall survival was 18.4 months [10.9–23.3], 9.7 months [6.9–16.6] and 29.3 months [26.3–36.1]. In multivariate analyses, progression (HR = 2.71 [1.79–4.10]) and death (HR = 2.79 [1.81–4.30]) were more likely for RASwt/BRAFmt vs RASwt/BRAFwt patients. Conclusions: BRAF mutations were associated with markedly poorer outcomes in initially unresectable RASwt mCRC patients treated by cetuximab in first‐line treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Ten‐year trend of opioid and nonopioid analgesic use in the French adult population.
- Author
-
Daveluy, Amélie, Micallef, Joëlle, Sanchez‐Pena, Paola, Miremont‐Salamé, Ghada, Lassalle, Régis, Lacueille, Clémentine, Grelaud, Angela, Corand, Virginie, Victorri‐Vigneau, Caroline, Batisse, Anne, Le Boisselier, Reynald, Peyrière, Hélène, Frauger, Elisabeth, Lapeyre‐Mestre, Maryse, and Haramburu, Françoise
- Subjects
- *
NONOPIOID analgesics , *ANALGESICS , *OPIOID analgesics , *OPIOID abuse , *OPIOIDS , *CONSUMPTION (Economics) , *ADULTS - Abstract
Aims: Analgesics are the most widely used medicines worldwide. In parallel, opioid abuse has increased and is of major concern. The accessibility of pharmacologically powerful medicines and the addictovigilance signals in France about the risk of opiates addiction call for an overview of analgesic use. The objective of this study was to investigate the use of analgesics reimbursed in France over a 10‐year period through its prevalence. Methods: A cross‐sectional study repeated yearly was conducted by using data from the French reimbursement database from 2006 to 2015. Analgesics were classified according to their pharmacological potency: prevalence of use for each category and sociodemographic characteristics of patients treated were analysed. Results: The annual prevalence of analgesic use was high and increased during the study period (59.8%, 253 976 users in 2015). In 2015, prevalence was always higher in women and increased with age, except for those older than 84 years. Peripheral analgesics were the most used (55.3%, 234 739 users). The prevalence of weak analgesic use decreased (21.3%, 90 257 users), mainly due to the definitive withdrawal of dextropropoxyphene in France in 2011, which was not offset by an increase in the consumption of other weak analgesics. For strong analgesics (1.2%, 5129 users), morphine was the most widely used, with a dramatic increase in oxycodone use, especially in the elderly. Conclusion: The prevalence of analgesic use is high: approximately 31 million adults had at least 1 analgesic reimbursed in 2015. The most widely used analgesics were peripheral analgesics, far ahead of opioid analgesics. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Factors associated with serious vehicular accidents: A cross‐sectional study in hospital emergency rooms.
- Author
-
Forest, Karelle, Valdenaire, Guillaume, Lorendeau, Jean‐Paul, Sagaspe, Patricia, Contrand, Benjamin, Durand‐Teyssier, Charlotte, Sakr, Dunia, Gil‐Jardine, Cédric, Boutreux, Sébastien, Lagarde, Emmanuel, Peyrouzet, Hélène, Lassalle, Régis, Moore, Nicholas, Philip, Pierre, and Girodet, Pierre‐Olivier
- Subjects
- *
TRAFFIC accidents , *MOTORCYCLING accidents , *HOSPITAL emergency services , *SUBSTANCE abuse , *ALCOHOLISM , *CROSS-sectional method - Abstract
Aims: Pictograms on medicine boxes warn of potential drug‐related driving hazard; we studied their association with serious accidents. Methods: Prospective study in emergency departments of the hospitals in Bordeaux and Périgueux (France), of drivers with serious (admitted at least 24 hours) or nonserious vehicular accidents. Minors, passengers, pedestrians or subjects incapable of answering an interview were excluded. Interviews ascertained driver and accident characteristics, use of drugs with or without pictograms, use of alcohol and abuse substances, sleepiness, distractions, and mind wandering at the time of the accident, Results: Between 18 October 2016 and 26 December 2018, 1200 of the 6212 drivers admitted to the hospital emergency rooms, 741 nonserious, 459 serious, were interviewed. Serious accidents were associated with male sex (odds ratio 1.89, 95% confidence interval [1.36–2.64]), age above 60 years (3.64 [2.21–6.00]), driving on local roads (3.34 [2.34–4.76]), driving a motorcycle (3.39 [2.29–5.00]), having drunk alcohol within 6 hours (2.89 [1.85–4.51]) and using a drug with a pictogram during the 24 hours previous to the accident (1.57 [1.06–2.32]). From 207 police reports, 101 drivers were not responsible, and 106 were responsible, associated with age below 40 years, driving in overcast or rainy weather (2.62 [1.29–5.33]), on local roads (3.89 [1.90–7.95]), and use of at least 1 pictogram drug in the previous week (3.12 [1.31–7.41]). Conclusion: The known risks of alcohol and pictogram drugs, of riding motorcycles and using local roads were confirmed. As measured, behavioural sleepiness did not predict accidents. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: a population-based study.
- Author
-
Panes, Arnaud, Pariente, Antoine, Bénard-Laribière, Anne, Lassalle, Régis, Dureau-Pournin, Caroline, Lorrain, Simon, Tournier, Marie, and Fourrier-Réglat, Annie
- Subjects
- *
HEALTH policy , *GUIDELINES , *CATATONIA , *SLEEP disorders , *ANXIETY disorders , *BENZODIAZEPINES - Abstract
Benzodiazepines and z-drugs are primarily indicated for the treatment of sleep disorders and anxiety symptoms. Their frequent long-term use contrasts with the international guidelines that limit treatment duration to a maximum of 4 weeks. The objective of this study was to assess the frequency of their use that was not in accordance with guidelines in the French general population between 2007 and 2012 and associated characteristics. A cohort of 67,550 benzodiazepine new users was set up in an exhaustive database for health-care reimbursements and representative of the French population. Benzodiazepine use not in accordance with guidelines was defined as the concomitant dispensation of several benzodiazepines, the dispensation of treatment over a period longer than recommended, or a new dispensing within the 2 months following the end of a previous treatment of maximum recommended duration, considering that French recommendations distinguish between hypnotic (4 weeks) and anxiolytic benzodiazepines (12 weeks). Benzodiazepine use not in accordance with guidelines was high, in about 30% of new hypnotic users and 20% of new anxiolytic users. Its frequency was stable over the study period. Associated characteristics were similar for new hypnotic or anxiolytic users, i.e.. older age, treatment initiation by a psychiatrist, presence of a chronic disease, hospitalization, or another psychotropic treatment. These findings provide a solid basis for establishing a public health policy to reduce benzodiazepine use not compliant with guidelines. They should be further explored in patients most at risk in the present study, e.g., patients treated by a psychiatrist. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Pharmacological treatment patterns in heart failure: a population-based cohort study.
- Author
-
Bosco-Lévy, Pauline, Favary, Clélia, Jové, Jérémy, Lassalle, Régis, Moore, Nicholas, and Droz-Perroteau, Cécile
- Subjects
- *
ADRENERGIC beta blockers , *ALDOSTERONE antagonists , *ACE inhibitors , *DEATH , *DIGOXIN , *DIURETICS , *HEART failure , *HETEROCYCLIC compounds , *HOSPITAL care , *LONGITUDINAL method , *MEDICAL records , *MEDICAL practice , *STATISTICAL sampling , *TIME , *PHYSICIAN practice patterns , *HEALTH insurance reimbursement , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *ACQUISITION of data methodology , *EVALUATION - Abstract
Background: Although the efficacy and safety of existing therapies of heart failure (HF) have been demonstrated in clinical trials, little is known about the treatment patterns in clinical practice, especially in France. Objectives: To describe the treatment initiation patterns and the subsequent treatment changes among HF patients, in the first year following an incident hospitalization for HF, in a French real-world setting. Methods: A cohort of patients aged ≥ 40 years, with an incident hospitalization for HF between 01/01/2008 and 31/12/2013, was identified in the 1/97th permanent random sample of the French nationwide claims database and followed 1 year. HF drug exposure—beta blockers (BB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), aldosterone antagonists (AA), diuretics, digoxin, or ivabradine—was assessed quarterly using a Proportion of Days Covered ≥ 66% (≥ 60 days out of the 90 days of the quarter), by considering HF drugs individually or in combination. Drug changes were assessed between each quarter. Results: Between 2008 and 2013, 7387 patients were included. Their mean age was 77.7 years (± 12.0 years) and 51.6% were women. During the follow-up, 24.4% died, 20% were not exposed to any HF treatment, 48.3 to 43.2% had diuretics, one third had BB or ACEI, 9% had ARB or AA, 6% had digoxin, and 2% had ivabradine. The main change occurred between the first and the second quarter for 53.1% of the initially untreated patients. Conclusion: This study provides valuable information on treatment patterns after an initial hospitalization for HF. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross‐national drug utilization study.
- Author
-
Ibáñez, Luisa, Sabaté, Mònica, Vidal, Xavier, Ballarin, Elena, Rottenkolber, Marietta, Schmiedl, Sven, Heeke, Andreas, Huerta, Consuelo, Martin Merino, Elisa, Montero, Dolores, Leon‐Muñoz, Luz María, Gasse, Christiane, Moore, Nicholas, Droz, Cécile, Lassalle, Régis, Aakjær, Mia, Andersen, Morten, De Bruin, Marie Louise, Groenwold, Rolf, and Ham, Hendrika A.
- Subjects
- *
DRUG utilization , *APIXABAN , *ANTICOAGULANTS , *ATRIAL fibrillation , *COMORBIDITY , *LONGITUDINAL method - Abstract
Aims: To estimate the incidence of direct oral anticoagulant drug (DOAC) use in patients with nonvalvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries. Methods: Longitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed. Results: A total of 186 405 new DOAC users (age ≥18 years) were identified. Standardized incidences varied from 1.93–2.60 and 0.11–8.71 users/10 000 (2011–2015) for dabigatran and rivaroxaban, respectively, and from 0.01–8.12 users/10 000 (2012–2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10 000 inhabitants in SIDIAP (Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only 1 database includes the total reference population (DNR) while others are considered a population representative sample (CPRD, BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4% (SIDIAP) and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in AOK Nordwest (Germany). Conclusion: Overall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There was variability in patient characteristics such as comorbidities, potentially interacting drugs and dose adjustment. (EMA/2015/27/PH). [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.
- Author
-
Guiard, Estelle, Lelievre, Bénédicte, Rouyer, Magali, Zerbib, Frank, Diquet, Bertrand, Mégraud, Francis, Tison, François, Bignon, Emmanuelle, Lassalle, Régis, Droz-Perroteau, Cécile, Moore, Nicholas, and Blin, Patrick
- Subjects
- *
TETRACYCLINES , *BISMUTH , *BIOACCUMULATION , *METALS in the body , *BLOOD sampling - Abstract
Introduction: A fixed-dose association of bismuth subcitrate, metronidazole and tetracycline (BMT) (Pylera®, Allergan, NJ, USA) was made available in France in 2013 for the eradication of Helicobacter pylori. Due to a historical issue of bismuth encephalopathy, the French Health Authorities requested a study of blood and plasma bismuth concentrations with BMT in daily practice.Aims: The aim of the study was to measure eventual bismuth accumulation and neurological toxicity in patients prescribed BMT.Methods: Patients initiating BMT for H. pylori between March 2014 and December 2015 were included. A blood sample was taken before first BMT intake and 24 h after the last intake, for assay of bismuth. A concentration > 50 μg/L was considered abnormal. Neurological complaints were assessed at inclusion, at the end of the 10-day treatment course, and 28 days later.Results: 202 patients were included, of whom 190 took at least one dose of BMT, and 167 provided both required blood samples. Mean blood bismuth concentrations after the BMT course were 16.9 μg/L (95% confidence interval 15.6-18.3). Concentrations were > 50 μg/L (56.0 μg/L and 50.9 μg/L) in two elderly patients, one of whom presented mild, transient memory impairment during treatment. Non-serious neurological symptoms occurred in 20% of all patients and treatment failure was documented in 5% of patients.Conclusions: In this study measuring blood bismuth concentrations in real-life practice, in < 1% of patients the BMT course resulted in blood bismuth concentrations > 50 μg/L. No serious neurological adverse events were observed.Study Registration: EU-PAS register EUPAS3142 at www.encepp.eu ; ENCePP study seal. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
21. Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.
- Author
-
Moore, Nicholas, Duret, Stéphanie, Grolleau, Adeline, Lassalle, Régis, Barbet, Vanessa, Duong, Mai, Thurin, Nicolas, Droz-Perroteau, Cécile, and Gulmez, Sinem Ezgi
- Subjects
- *
LIVER injuries , *MEDICAL care , *LIVER diseases , *HEPATOTOXICOLOGY , *MEDICAL coding - Abstract
Introduction: Acute liver injury (ALI) is a major reason for stopping drug development or removing drugs from the market. Hospitalisation for ALI is relatively rare for marketed drugs, justifying studies in large-scale databases such as the nationwide Système National des Données de Santé (SNDS), which covers 99% of the French population.Methods: SNDS was queried over 2010-2014 for all hospital admissions for acute toxic liver injuries not associated with a possible other cause, using a case-population approach. Exposures of interest were drugs dispensed from 7 to 60 days before date of admission. Individual drugs were analysed by their frequency (if five or more cases) and by the ratio of exposed cases to the number of exposed subjects and to exposed patient-time in the general population over the same timeframe.Results: Over 5 years, 4807 cases of ALI were identified, mean age 54.5, 59% women, 76% exposed to at least one of 249 different drugs. Drugs most commonly identified were non-overdose paracetamol (31% of cases), esomeprazole or omeprazole (18%), phloroglucinol, domperidone, co-amoxiclav, furosemide, and atorvastatin (more than 250 cases each). When compared to population exposures, the highest per-person risks were observed with antimycobacterial antibiotics, with one case for 1000 or fewer users, followed by colestyramine and erythromycin (around 1/5300), antiepileptic drugs, anticoagulants, and anti-Alzheimer drugs (1/6000-1/10,000 users). When a person-time approach was considered, the drugs with the highest per-tablet risk were still the antituberculosis drugs, followed by a number of other antibiotics.Conclusions: This nationwide study describes drugs associated with ALI, according to absolute population burden and per-patient and per-tablet risk. Some of these associations may be spurious, others causal, and others yet were unexpected. Systematic analysis of drug classes will look for outliers within each class that could raise signals of unexpected hepatic toxicity. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
22. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
- Author
-
Blin, Patrick, Samama, Charles-Marc, Sautet, Alain, Benichou, Jacques, Lignot-Maleyran, Séverine, Lamarque, Stéphanie, Lorrain, Simon, Lassalle, Régis, Droz-Perroteau, Cécile, Mismetti, Patrick, and Moore, Nicholas
- Subjects
- *
ANTICOAGULANTS , *HEPARIN , *VENOUS thrombosis , *THROMBOEMBOLISM , *POISSON processes - Abstract
Graphical abstract Abstract Background Venous thromboembolism (VTE) after total knee or hip replacement (TKR, THR) is usually prevented with low-molecular weight heparin (LMWH), and increasingly by direct oral anticoagulants (DOAC). The aim of the present study was to compare the benefit-risk and medical costs of DOAC vs. LMWH in a real-life setting. Methods All patients with THR or TKR in France between Jan-1st 2013 and Sep-30th 2014, discharged to home, were identified and followed-up for 3 months in the French nationwide claims database, SNDS. DOAC users were 1:1 matched with LWMH users on gender, age and propensity score. Relative risks (RR) of hospitalized VTE, hospitalized bleeding and death were estimated using quasi-Poisson models. Medical costs were calculated according to the societal perspective, including total cost for outpatient claims and national DRG costs for hospitalisations. Results Most DOAC users (≥ 98.8%) were matched to a LMWH patient. For the 63,238 matched THR patients, the 3-month absolute risk of VTE was 0.9‰ with DOAC and 2.5‰ with LMWH (RR = 0.35 [0.23 to 0.54]), of bleeding 1.8‰ and 2.1‰ (0.88 [0.62–1.25]), death 0.7‰ and 1.1‰ (0.68 [0.40–1.15]). For the 31,440 matched TKR patients, risks were 1.6‰ and 2.3‰ (0.69 [0.42–1.16]) for VTE, 2.4‰ and 3.8‰ (0.64 [0.43 to 0.97]) for bleeding, and 0.6‰ and 0.8‰ (0.69 [0.30–1.62]) for all-cause death. Mean medical costs were 28% and 21% lower with DOAC than LMWH for THR and TKR, respectively. This nationwide study found a very low risk of VTE, hospitalized bleeding and death after THR or TKR discharge in patients with VTE prevention in real-life setting, with better benefit-risk profiles of DOAC compared to LMWH, and associated cost savings. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.
- Author
-
Overbeek, Jetty A., Heintjes, Edith M., Prieto-Alhambra, Daniel, Blin, Patrick, Lassalle, Régis, Hall, Gillian C., Lapi, Francesco, Bianchini, Elisa, Hammar, Niklas, Bezemer, Irene D., and Herings, Ron M.C.
- Abstract
Purpose The aim of this study was to determine the similarities and differences of type 2 diabetes mellitus (T2DM) treatment patterns in daily practice in 5 European countries and whether these reflect differences in guidelines. Methods Prescriptions for drugs used in diabetes treatment during a 5-year study period were obtained from electronic databases. Patients initiating T2DM treatment during the study period were included. An SAS analysis tool was developed to create episodes of use of drug classes, which resulted in treatment patterns. Findings A total of 253,530 patients initiating T2DM treatment during the study period were included; 52% to 55% were male, and the mean age ranged from 62 to 67 years. Metformin was the most common initial treatment in all countries. After initial therapy, most patients in the Netherlands, Spain, and the United Kingdom switched to a combination of metformin + a sulfonylurea derivative (SU). In Italy, metformin in combination with an SU was outnumbered by “other treatment,” mainly because of repaglinide use. In France, treatments including dipeptidyl peptidase-4 inhibitors were most frequent as second- and fourth-line treatment. Metformin monotherapy was again most commonly observed as the third line of treatment in all countries. Fourth treatment was a combination of metformin + an SU in the Netherlands and Spain; in the United Kingdom and France, dipeptidyl peptidase-4 inhibitors were the most frequently used fourth line of treatment. Implications This study provides a comprehensive overview of T2DM treatment patterns among patients initiating T2DM treatment in 5 European countries. There were differences, especially regarding the uptake of newer incretin-based treatments, which are usually prescribed as a second and/or third treatment in agreement with local guidelines. These variations reflect the differences between the national guidelines of these countries. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
24. Usage patterns of paracetamol in France.
- Author
-
Duong, Mai, Gulmez, Sinem Ezgi, Salvo, Francesco, Abouelfath, Abdelilah, Lassalle, Régis, Droz, Cécile, Blin, Patrick, and Moore, Nicholas
- Subjects
- *
DRUG side effects , *ACETAMINOPHEN , *DRUG interactions , *FEVER , *CARDIOVASCULAR agents - Abstract
Aims The aim of the present study was to describe the real-life usage patterns of paracetamol. Methods The Echantillon Généraliste de Bénéficiaires (EGB) database, the permanent 1/97 representative sample from the French national healthcare insurance system, was searched in 2011 to identify usage patterns, concomitant chronic diseases and use of cardiovascular medication in users prescribed single-ingredient (SP) and combination (CP) paracetamol, representing 85% of all sales. Results Of 526 108 subjects aged ≥15 years in the EGB, 268 725 (51%) had paracetamol dispensed on ≥1 occasion; of these, 207 707 (77%) were dispensed only SP and 61 018 (23%) received CP with or without SP. SP users were younger (48.3 years vs. 50.5 years), and 57% of SP users vs. 58% of CP users were female. Chronic comorbidities were more common in CP than SP users. SP users had, on average, 3.4 dispensings per year vs. 5.0 for CP users, for 36 defined daily doses (DDD, 3 g) of SP vs. 53 DDD per year for CP; 49% SP users bought 14 DDD or fewer; 15% bought >60 DDD. Use of paracetamol increased with age from about 16 DDD per year in 15-30-year-olds to over 90 DDD per year in patients above the age of 75; 53% of patients ≤60 years bought fewer than 14 DDD per year, whereas 55% of those >60 bought more than 30 DDD per year. More than half the dispensings exceeded the legal per-box limit of 8 g. Conclusions Over 50% of the French adult population were dispensed paracetamol at least once over the course of a year, generally for short-term use. Considering recent misgivings on the real efficacy and safety of paracetamol, such widespread use might have important public health consequences. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
- Author
-
Bouchet, Stéphane, Poulette, Sylvie, Titier, Karine, Moore, Nicholas, Lassalle, Régis, Abouelfath, Abdelilah, Italiano, Antoine, Chevreau, Christine, Bompas, Emmanuelle, Collard, Olivier, Duffaud, Florence, Rios, Maria, Cupissol, Didier, Adenis, Antoine, Ray-Coquard, Isabelle, Bouché, Olivier, Le Cesne, Axel, Bui, Binh, Blay, Jean-Yves, and Molimard, Mathieu
- Subjects
- *
DRUG therapy , *TREATMENT effectiveness , *DRUG monitoring , *LONGITUDINAL method , *REGRESSION analysis , *GASTROINTESTINAL tumors , *IMATINIB , *PROPORTIONAL hazards models , *DESCRIPTIVE statistics , *LOG-rank test , *PROGNOSIS - Abstract
Background Imatinib has dramatically improved the prognosis of advanced gastrointestinal stromal tumours (GISTs). Clinical trial data showed that patients with trough imatinib plasma concentrations (Cmin) below 1100 ng/ml (quartile 1) had shorter time to progression, but no threshold has been defined. The main objective of this study was to investigate in advanced GIST whether a Cmin threshold value associated with a longer progression-free survival (PFS) could be specified. This would be the first step leading to therapeutic drug monitoring of imatinib in GIST. Patients and methods Advanced GIST patients (n = 96) treated with imatinib 400 mg/d (41 stomach, 34 small bowel, and 21 other primary site localisations) were prospectively included in this real-life setting study. Routine plasma level testing imatinib (Cmin) and clinical data of were recorded prospectively. Results Small bowel localisation was associated with an increased relative risk of progression of 3.09 versus stomach localisation (p = 0.0255). Mean Cmin (±standard deviation) was 868 (±536) ng/ml with 75% inter-individual and 26% intra-patient variability. A Cmin threshold of 760 ng/ml defined by log-rank test was associated with longer PFS for the whole population (p = 0.0256) and for both stomach (p = 0.043) and small bowel (p = 0.049) localisations when analysed separately. Multivariate Cox regression analysis found that Cmin above 760 ng/ml was associated with 65% reduction risk of progression (p = 0.0271) in the whole population independently of the anatomical localisation. Conclusion Concentration of imatinib significantly influences duration of tumour control treatment in GIST patients with a Cmin threshold of 760 ng/ml associated with prolonged PFS in real-life setting. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study.
- Author
-
Gulmez, Sinem Ezgi, Larrey, Dominique, Pageaux, Georges‐Philippe, Bernuau, Jacques, Bissoli, Franco, Horsmans, Yves, Thorburn, Douglas, McCormick, P. Aiden, Stricker, Bruno, Toussi, Massoud, Lignot‐Maleyran, Séverine, Micon, Sophie, Hamoud, Fatima, Lassalle, Régis, Jové, Jérémy, Blin, Patrick, and Moore, Nicholas
- Subjects
- *
LIVER failure , *LIVER diseases , *ACETAMINOPHEN , *DRUG overdose , *DRUG toxicity - Abstract
Aims Acute drug overdose, especially with paracetamol, may cause acute liver failure leading to registration for transplantation (ALFT). Population statistics and between-country differences for ALFT related to overdose have been poorly described. The aim of the present study was to evaluate overdose ALFT in the multi-country Study of Acute Liver Transplantation (SALT). Methods All adult overdose-related ALFT, with or without suicidal intent, in France, Greece, Ireland, Italy, the Netherlands, Portugal and the UK between 2005 and 2007 were identified from liver transplant registries and hospital records. These were compared with whole-country and per capita use of paracetamol. Results Six hundred cases of ALFT were identified in 52 of 57 eligible transplant centres, of which 114 involved overdose (72 intentional, 10 non-intentional, 32 uncertain). Overdose represented 20% of all-cause ALFT: Ireland 52%, UK 28%, France 18%, the Netherlands 8%, and Italy 1%. Overdose ALFT were mostly females (61%), mean age 33.6 ± 10.9 years. A total of 111 (97%) of the overdoses involved paracetamol. Event rates ranged from one ALFT for 20.7 tons of paracetamol in Ireland, to one for 1074 tons in Italy and one case in 60 million inhabitants over 3 years in Italy to one case in 286 000 inhabitants per year in Ireland. Per-country event rates for non-overdose ALFT exposed to paracetamol were between 2.5 and 4.0 per million treatment-years sold. Conclusions Paracetamol overdose was found to represent one-sixth of all-cause ALFT. There was a 50-fold difference in Europe in the rates of paracetamol overdose ALFT, and a 200-fold difference per million inhabitants. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study.
- Author
-
Fourrier-Réglat, Annie, Noize, Pernelle, Facon, Thierry, Fermand, Jean-Paul, Fitoussi, Olivier, Marit, Gérald, Thomaré, Patrick, Robinson, Philip, Bignon, Emmanuelle, Jové, Jérémy, Lassalle, Régis, Rouyer, Magali, Grelaud, Angela, and Moore, Nicholas
- Subjects
- *
HEALTH outcome assessment , *MULTIPLE myeloma treatment , *CANCER chemotherapy , *BORTEZOMIB , *IMMUNOGLOBULIN G , *DEXAMETHASONE - Abstract
In response to a regulatory request for real-life data on patterns of use and survival outcomes, 793 patients initiating bortezomib for multiple myeloma in France (May 2004-April 2006) were included in this observational study. Data were collected from medical files and patients were followed for 2 years, with vital status collected after 3 years. In total 779 patients were analyzed: 83.1% had immunoglobulin G (IgG) or IgA M-component, mean age was 65.7 years and 46.5% were female. Bortezomib was initiated as third-or-later line in 82.0%. For 75.9%, the starting dose was 1.3 mg/m2; 42.6% had bortezomib alone, 54.0% with dexamethasone. The mean number of bortezomib cycles was 5.0. Three-year overall survival from bortezomib initiation was 31.4% (95% confidence interval, CI [28.1; 34.7]) and median overall survival was 19.6 months. Two-year progression-free survival was 12.0% (95% CI [9.8; 14.4]), and median progression-free survival was 7.2 months. Overall best response was 44.0%. Survival outcomes during real-life use of bortezomib were within the range of those reported in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
28. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
- Author
-
Bouchet, Stéphane, Titier, Karine, Moore, Nicholas, Lassalle, Régis, Ambrosino, Basmah, Poulette, Sylvie, Schuld, Peter, Belanger, Coralie, Mahon, François‐Xavier, and Molimard, Mathieu
- Subjects
- *
DRUG monitoring , *IMATINIB , *TREATMENT of chronic myeloid leukemia , *ADVERSE health care events , *DRUG dosage , *COHORT analysis , *MEDICAL research - Abstract
This study set out to examine in a large real-life cohort of patients with chronic myeloid leukemia (CML) the impact of imatinib threshold of 1000 ng/mL on molecular response, as suggested in a small subset of patients. Patient plasma samples were submitted from around France to a central facility, free of charge under the auspices of the European Treatment and Outcome Study (EUTOS) for CML. Submitting physicians were required to complete an 'imatinib monitoring request form', including details of why therapeutic drug monitoring (TDM) was requested, dose and duration of imatinib treatment, cytogenetic and molecular response, adverse events, and concurrent medications. Imatinib trough plasma concentration ( Cmin) was measured at the central facility. Among 1985 eligible plasma samples analyzed, from 1216 CML patients, imatinib Cmin correlated positively with reported imatinib dose, but interpatient variability in Cmin was high (60%). A logistic regression analysis revealed that treatment duration and imatinib Cmin > 1000 ng/ mL were significantly associated with major and complete molecular responses with odds ratios of 1.69 and 2.08, respectively. These data support in real-life setting that imatinib Cmin threshold of 1000 ng/mL is associated with major and complete molecular response and that TDM could play an important role in dose optimization. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
29. Causality of Drugs Involved in Acute Liver Failure Leading to Transplantation: Results from the Study of Acute Liver Transplant (SALT).
- Author
-
Gulmez, Sinem Ezgi, Moore, Nicholas, Pageaux, Georges-Philippe, Lignot, Severine, Horsmans, Yves, Stricker, Bruno, Bernuau, Jacques, Bissoli, Franco, Thorburn, Douglas, Montastruc, Jean-Louis, Micon, Sophie, Hamoud, Fatima, Lassalle, Régis, Jové, Jérémy, Blin, Patrick, and Larrey, Dominique
- Abstract
Background: Several methods have been proposed to assess causality in drug-induced liver injury but none have been tested in the specific context of acute liver failure leading to transplantation (ALFT).Objective: We took advantage of the Study of Acute Liver Transplant (SALT), a European case-population study of ALFT, to test different causality scales.Methods: Causality was assessed by experts in SALT, a 7-country case-population study from 2005 to 2007 of adult otherwise unexplained ALFT, for all drugs found within 30 days prior to the date of initial symptoms of liver disease (index date), using information content, causality scales, and data circuit determined from a pilot study, Salome.Results: The consensus points from Salome were to provide full data on drugs including international non-proprietary name (INN) and doses except for non-steroidal anti-inflammatory drugs (NSAIDs) and to use the World Health Organization (WHO) causality scale. In SALT, among the 9,479 identified patients, 600 (6.3%) were cases of ALFT, of which 187 had been exposed to drugs within 30 days, without overdose. In 130 (69.5%) of these the causality score was possible, probable, or highly probable.Conclusion: In ALFT cases, once other clinical causes have been excluded and drug exposure established within 30 days, the main discriminant characteristic for causality will be previous knowledge of possible hepatotoxicity. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
30. Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen).
- Author
-
Gulmez, Sinem, Larrey, Dominique, Pageaux, Georges-Philippe, Lignot, Severine, Lassalle, Régis, Jové, Jérémy, Gatta, Angelo, McCormick, P., Metselaar, Harold, Monteiro, Estela, Thorburn, Douglas, Bernal, William, Zouboulis-Vafiadis, Irene, Vries, Corinne, Perez-Gutthann, Susana, Sturkenboom, Miriam, Bénichou, Jacques, Montastruc, Jean-Louis, Horsmans, Yves, and Salvo, Francesco
- Subjects
- *
ACETAMINOPHEN , *LIVER failure , *LIVER transplantation , *DRUG efficacy , *NONSTEROIDAL anti-inflammatory agents - Abstract
Background: Most NSAIDs are thought to be able to cause hepatic injury and acute liver failure (ALF), but the event rates of those leading to transplantation (ALFT) remain uncertain. Objectives: The aim of the study was to estimate population event rates for NSAID-associated ALFT Methods: This was a case-population study of ALFT in 57 eligible liver transplant centres in seven countries (France, Greece, Ireland, Italy, The Netherlands, Portugal and the UK). Cases were all adults registered from 2005 to 2007 for a liver transplant following ALFT without identified clinical aetiology, exposed to an NSAID or paracetamol (acetaminophen) within 30 days before the onset of clinical symptoms. NSAID and paracetamol population exposures were assessed using national sales data from Intercontinental Marketing Services (IMS). Risk was estimated as the rate of ALFT per million treatment-years (MTY). Results: In the 52 participating centres, 9479 patients were registered for transplantation, with 600 for ALFT, 301 of whom, without clinical aetiology, had been exposed to a drug within 30 days. Of these 301 patients, 40 had been exposed to an NSAID and 192 to paracetamol (81 of whom were without overdose). Event rates per MTY were 1.59 (95 % CI 1.1-2.2) for all NSAIDs pooled, 2.3 (95 % CI 1.2-3.9) for ibuprofen, 1.9 (95 % CI 0.8-3.7) for nimesulide, 1.6 (95 % CI 0.6-3.4) for diclofenac and 1.6 (95 % CI 0.3-4.5) for ketoprofen. For paracetamol, the event rate was 3.3 per MTY (95 % CI 2.6-4.1) without overdoses and 7.8 (95 % CI 6.8-9.0) including overdoses. Conclusions: ALF leading to registration for transplantation after exposure to an NSAID was rare, with no major difference between NSAID. Non-overdose paracetamol-exposed liver failure was twice more common than NSAID-exposed liver failure. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
31. Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France.
- Author
-
Guelfucci, Florent, Clay, Emilie, Aballéa, Samuel, Lassalle, Régis, Moore, Nicholas, and Toumi, Mondher
- Subjects
- *
TYPE 2 diabetes treatment , *TYPE 2 diabetes , *ALGORITHMS , *OUTPATIENT medical care , *COMBINED modality therapy , *KIDNEYS , *MEDICAL care costs , *REGRESSION analysis , *RESEARCH funding , *STATISTICAL sampling , *HEALTH insurance reimbursement , *CROSS-sectional method , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics , *ECONOMICS - Abstract
Background: This study compares annual ambulatory care expenditures per patient with type 2 diabetes mellitus (T2DM) in France according to treatment phase and renal function status. Methods: Records from patients with T2DM were extracted from a health insurance database. Patients were classified in subgroups, by treatment phase: oral/GLP1 monotherapy, double therapy, triple therapy or insulin therapy, and according to renal function status (identified using pharmacy, lab and consultation claims). Annual ambulatory expenditures were estimated from the national insurance perspective by year (from 2005 to 2010) and subgroup. Results: The number of patients ranged from 9,682 to 11,772 between 2005 and 2010. The average annual expenditure per individual in 2010 ranged from €3,017 (standard deviation: €3,829) for monotherapy to €3,609 ± €3,801 for triple therapy, and €7,398 ± €5,487 with insulin (adjusted ratio insulin therapy/monotherapy: 2.36, p < 0.001). Similar differences between treatement stages were found in previous years. Additional costs for insulin were mainly related to nursing care (multiplied by 18.42, p < 0.001), medical devices and pharmacy costs. DM-attributable drug costs were mainly related to antidiabetic drugs (28% for monotherapy to 71% for triple therapy), but also to cardiovascular system drugs (21% for monotherapy to 51% with insulin) and nervous system drugs (up to 8% with insulin). Declining renal function was associated with an increase in expenses by 12% to 53% according to treatment stage. Conclusions: Overall, ambulatory care expenditures increase with treatment escalation and declining renal function amongst patients with T2DM. Insulin therapy is associated with substantially increased costs, related to pharmacy, nursing care and medical device costs. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
32. Effectiveness of antibiotics for acute sinusitis in real-life medical practice.
- Author
-
Blin, Patrick, Blazejewski, Sylvie, Lignot, Séverine, Lassalle, Régis, Bernard, Marie-Agnès, Jayles, Delphine, Théophile, Hélène, Bénichou, Jacques, Demeaux, Jean-Louis, Ebbo, David, Franck, Jacques, Moride, Yola, Peyramond, Dominique, Rouveix, Bernard, Sturkenboom, Miriam, Gehanno, Paul, Droz, Cécile, and Moore, Nicholas
- Subjects
- *
PHYSIOLOGICAL effects of antibiotics , *SINUSITIS treatment , *DRUG efficacy , *DRUG prescribing , *STATISTICAL sampling , *MEDICAL practice - Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Determining bacterial aetiology of acute sinusitis is difficult without employing invasive procedures. • Most episodes of acute sinusitis resolve spontaneously. • Antibiotics have demonstrated efficacy for the treatment of acute bacterial sinusitis in clinical trials yet little is known of their effectiveness in real-life treatment settings. WHAT THIS STUDY ADDS • Most cases of untreated acute sinusitis resolved spontaneously. Antibiotics were more effective when given within the first 10 days of treatment. This had no effect on later recurrence. • Patients with poor oro-dental condition or recent antibiotic use may derive the most benefit from an antibiotic prescription and this should be considered by prescribers. • The antibiotics used were found to be equally effective. • Existing recommendations to identify acute sinusitis with high probability of bacterial origin, such as the French recommendations, fever or duration of symptoms fail to identify patients in whom antibiotics are more effective. AIMS To assess the effectiveness of antibiotics in acute bacterial sinusitis. METHODS This was a prospective cohort study with 2 months follow-up of 5640 patients with acute sinusitis included by a random sample from 1174 GPs and 120 ENT specialists. Main outcomes were short-term initial success, defined as the absence of prescription of (another) antibiotic or sinus lavage within 10 days, and lack of recurrence between the 11th and 60th day, after initial success. RESULTS Initial success was found in 88.7% (95% CI 85.1, 91.4%) of patients without antibiotic prescription at inclusion and 96.2% (95% CI 95.7, 96.7%) of patients prescribed antibiotics. The 10 day adjusted hazard ratio (HR) for treatment failure (new antibiotic prescription or sinus drainage) with initial antibiotics compared with no antibiotics was 0.30 (95% CI 0.21, 0.42) with no difference between antibiotics. Antibiotics were more effective in patients with poor oro-dental condition (HR 0.04, 95% CI 0.01, 0.20) and in patients who had already used antibiotics during the previous 2 months (HR 0.09, 95% CI 0.03, 0.28). For patients without failure at 10 days, recurrence between the 11th and 60th day was similar whether or not they had initially been prescribed an antibiotic, 94.1% (95% CI 93.4, 94.7%) and 93.4% (95%CI 90.3, 95.5%), respectively. CONCLUSION Most acute sinusitis cases not prescribed antibiotics resolve spontaneously. Antibiotics reduced by 3.3-fold the risk of failure within 10 days, without impact on later recurrence. The greatest benefit of antibiotics was found for patients with poor oro-dental condition or with antibiotic use within the previous 2 months. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
33. Treatment of high fat diet induced type 2 diabetes in C57BL/6J mice by two medicinal plants used in traditional treatment of diabetes in the east of Algeria
- Author
-
Hamza, Nawel, Berke, Bénédicte, Cheze, Catherine, Le Garrec, Raphaële, Lassalle, Régis, Agli, Abdel-Nacer, Robinson, Philip, Gin, Henri, and Moore, Nicholas
- Subjects
- *
BLOOD sugar analysis , *INSULIN resistance , *TYPE 2 diabetes prevention , *ALTERNATIVE medicine , *ANALYSIS of variance , *ANIMAL experimentation , *BIOPHYSICS , *CHOLESTEROL , *COMPUTER software , *HYPOGLYCEMIC agents , *INSULIN , *RESEARCH methodology , *MEDICINAL plants , *MICE , *MULTIVARIATE analysis , *REGRESSION analysis , *PLANT extracts , *DATA analysis , *STATISTICAL significance , *PHARMACODYNAMICS , *PREVENTION - Abstract
Abstract: Aim of the study: Hydro-alcoholic extracts of Centaurium erythraea Rafn (CE), Gentianaceae and Artemisia herba-alba Asso (AHA), Asteraceae, medicinal plants used in traditional treatment of diabetes in north-eastern Algeria, were tested in established type 2 diabetes induced with a standardized high fat diet (HFD) in mice. Materials and methods: After confirmation of diabetes (17th week), plant extracts were administered orally by gavage at a dose of 2g/kg daily for 18 weeks to male C57BL/6J mice fed HFD. Animals were weighed, food intake and plasma glucose measured weekly, insulin and lipid profile at study end. Results: At 35 weeks, groups treated with AHA or CE vs. HFD control had a significant reduction in mean (±SD) fasting blood glucose concentrations (143.8±23.9 and 139.5±14.2 vs. 229.0±20.8mg/dL, p <0.05, respectively), triglyceride (18.9±11.1 and 16.0±6.5 vs. 62.8±18.3mg/dL, p <0.05), total cholesterol (1.2±0.1 and 1.2±0.3 vs. 1.8±1.1g/L, p <0.05) and serum insulin concentrations (1.7±0.7 and 0.9±0.7 vs. 3.3±14.3ng/mL, p <0.05). Plant extracts also markedly reduced insulin resistance as compared to HFD controls (AHA: 15.6±9.1, CE: 9.0±7.7 vs. HFD control 38.5±30.3, p <0.05). The plant extracts decreased calorie intake and had little effect on body weight or HDL-cholesterol. Conclusion: AHA has already been shown to have a antihyperglycaemic and antihyperlipidemic effect but this is the first demonstration of an effect of AHA and CE on established HFD-induced diabetes. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
34. EFFECTIVENESS AND SAFETY OF STANDARD AND REDUCED DOSES OF DABIGATRAN COMPARED TO RIVAROXABAN IN NONVALVULAR ATRIAL FIBRILLATION: LONG-TERM RESULTS FROM A COHORT STUDY IN THE FRENCH NATIONWIDE CLAIMS DATABASE.
- Author
-
Moore, Nicholas, Blin, Patrick, Cottin, Yves, Dureau-Pournin, Caroline, Abouelfath, Abdelilah, Lassalle, Régis, Guiard, Estelle, Balestra, Aurélie, Mismetti, Patrick, de Pouvourville, Gérard, Bénichou, Jacques, and Droz-Perroteau, Cécile
- Subjects
- *
ATRIAL fibrillation , *SAFETY standards , *RIVAROXABAN , *ACUTE coronary syndrome , *COHORT analysis - Published
- 2020
- Full Text
- View/download PDF
35. Abstract 15864: Effectiveness and Safety of Standard and Reduced Doses of Dabigatran versus Rivaroxaban in Non-Valvular Atrial Fibrillation: A Cohort Study in the French Nationwide Claims Database SNDS.
- Author
-
Moore, Nicholas, Cottin, Yves, Dureau-Pournin, Caroline, Abouelfath, Abdelilah, Lassalle, Régis, Bénichou, Jacques, De Pouvourville, Gérard, Mismetti, Patrick, Droz-Perroteau, Cécile, and Blin, Patrick
- Subjects
- *
ATRIAL fibrillation , *SAFETY standards , *ACUTE coronary syndrome , *RIVAROXABAN , *HEART valve diseases , *STROKE - Abstract
Introduction: Dabigatran (D) and rivaroxaban (R) showed a better benefit-risk than VKA for stroke prevention in non-valvular atrial fibrillation (NVAF), but no randomized trial has compared D to R. Objectives: The objective was to compare the 2-year risk of major events in real-life use for NVAF in new users of standard doses (D150mg vs R20mg) and reduced doses (D110mg vs R15mg). Methods: Cohorts of D or R new users for NVAF in 2013 identified and followed 2 years in the SNDS French nationwide claims database. NVAF was defined from long-term disease registration, hospitalisation diagnosis or procedure for atrial fibrillation, without valvular disease (3-year history). D and R patients were 1:1 matched according to dose, on gender, age, drug start date and high-dimensional propensity scores (hdPS) including individual risk factors from CHA2DS2-VASc and HAS-BLED scores. Hazard ratios (HR) [95% confidence interval] were estimated on-treatment, using Cox proportional hazard risk or Fine and Gray models. Results: From the 10,847 D150, 15,532 D110, 18,829 R20 and 11,195 R15 new users for NVAF in 2013, 8,290 D150/R20 per arm, and 7,639 D110/R15 per arm were matched, i.e. 76% and 68% of the smallest group (D150 and R15 groups), respectively, with all standardized differences <0.1, most <0.02, and a good overlap of hdPS distributions. Patients on standard dose were younger than those with reduced dose (mean 66.9 and 80.4 years, respectively), with fewer stroke and bleeding risk factors (58.9% and 94.0% CHA2DS2-VASc > 2, 15.6% and 34,0% HAS-BLED ≥ 3, respectively). The D vs R HR for clinically relevant bleeding was 0.55 [0.43-0.70] for standard dose and 0.77 [0.64-0.92] for reduced dose, and respectively 0.92 [0.67-1.26] and 0.73 [0.56-0.94] for stroke and systemic embolism, 0.93 [0.66-1.29] and 0.95 [0.71-1.26] for acute coronary syndrome, 0.84 [0.65-1.11] and 0.95 [0.83-1.09] for death, and 0.74 [0.64-0.86] and 0.88 [0.79-0.97] for the composite of the 4 major events. Conclusions: This nationwide study shows that in a real-world setting, standard and reduced doses of dabigatran or rivaroxaban were not given to the same new users for NVAF, but in both doses there was a better benefit-risk for dabigatran than for rivaroxaban. [ABSTRACT FROM AUTHOR]
- Published
- 2018
36. Abstract 14523: Two-Year Benefit-Risk of Standard and Reduced Doses of Rivaroxaban versus Vitamin-K Antagonists in Non-Valvular Atrial Fibrillation: A Cohort Study in the French Nationwide Claims Database.
- Author
-
Moore, Nicholas, Fauchier, Laurent, Dureau-Pournin, Caroline, Bernard, Marie-Agnès, Lassalle, Régis, Sacher, Frédéric, Dallongeville, Jean, Droz-Perroteau, Cécile, and Blin, Patrick
- Subjects
- *
ATRIAL fibrillation , *RIVAROXABAN , *KIDNEY failure , *VITAMIN K , *COHORT analysis , *STROKE , *REPORTING of diseases - Abstract
Introduction: Real-life benefit and risk for stroke prevention in non-valvular atrial fibrillation (NVAF) of rivaroxaban 20mg (R20), the standard dose, and rivaroxaban 15mg (R15), the recommended dose for patients with moderate or severe renal failure, remain uncertain. Objectives: The objective was to compare the 2-year risk of major events in NVAF new users of R20 or R15 versus vitamin K antagonists (VKA) in real-life setting. Methods: A cohort of R20, R15 or VKA new users for NVAF in 2013 was identified and followed for 2 years in SNDS, the French nationwide claims database. NVAF was defined from long-term disease registration, hospitalisation diagnosis or procedure for atrial fibrillation, without rheumatic valve disease or valve replacement (3-year history). Rivaroxaban and VKA patients were 1:1 matched on gender, age, date of the first drug dispensing, and high-dimensional propensity score (hdPS) including individual risk factors from CHA2DS2-VASc and HAS-BLED scores. Hazard Ratios (HR) [95% Confidence Interval (CI)] were estimated on-treatment, using Cox proportional hazards risk or Fine and Gray models. Results: Of 118,048 new anticoagulant users for NVAF in 2013, 15,680 and 12,018 per arm were matched for R20 versus VKA and R15 versus VKA, respectively, with small or no standardized differences between groups, and a good overlap of hdPS distributions. Matched patients of R20 and R15 comparisons, had mean age 71.3 and 80.4 years, with 75.9% and 93.2% CHA2DS2-VASc ≥ 2 and 25.7% and 38.5% HAS-BLED ≥ 3, respectively. For R20 versus VKA and R15 versus VKA, there was no difference for stroke and systemic embolism (0.99 [0.84-1.16] and 1.14 [0.97-1.34], respectively), but a significantly lower risk of major bleeding for both doses of rivaroxaban (0.69 [0.59-0.81] and 0.80 [0.69-0.93]), as well as of death (0.67 [0.61-0.74] and 0.79 [0.73-0.85]) and for the composite of the 3 major events (0.73 [0.68-0.79] and 0.83 [0.77-0.88]). Conclusions: This nationwide cohort study of new anticoagulant users for NVAF shows for both doses of rivaroxaban (20mg and 15mg) a better risk profile with fewer major bleedings compared to VKA, no difference for stroke and systemic embolisms, and a better benefit-risk with fewer deaths and the 3 major events taken together. [ABSTRACT FROM AUTHOR]
- Published
- 2018
37. An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France.
- Author
-
Blin, Patrick, Demoly, Pascal, Drouet, Martine, Falissard, Bruno, Lignot-Maleyran, Séverine, Maizi, Hélène, Lorrain, Simon, Lassalle, Régis, Droz-Perroteau, Cécile, Moore, Nicholas, and Molimard, Mathieu
- Subjects
- *
ALLERGIC rhinitis , *ALLERGENS , *POLLEN , *IMMUNOTHERAPY , *RHINITIS - Abstract
Background: Allergic rhinitis affects around one quarter of the Western European population. Prophylactic allergen immunotherapy may be useful to reduce the risk of acute symptomatic attacks (hayfever). A five-grass pollen extract sublingual immunotherapy (5GPE-SLIT) has been developed for the treatment of allergic rhinitis to grass pollen. The objective of this study was to describe real-world treatment patterns with 5GPE-SLIT in France with respect to the prescribing information. Methods: This prospective cohort study was conducted by 90 community and hospital allergists. Adults and children (> 5 years old) starting a first treatment with 5GPE-SLIT prior to the 2015 pollen season were eligible. Data was collected at the inclusion visit and at the end of the pollen season. The primary outcome variable was compatibility of 5GPE-SLIT prescription with the prescribing information. This was determined with respect to four variables: (1) interval between 5GPE-SLIT initiation and onset of the pollen season ≥ 3 months, (2) age of patient ≥ 5 years, (3) intermittent symptoms or mild symptom severity (4) confirmatory diagnostic test. At study end, symptoms reported during the pollen season and any modifications to treatment or adverse events were documented. Results: 280 adults and 203 children were enrolled. The prescribing information was respected for 82.5% of adults and 86.7% of children. A skin test was performed for all patients. 5GPE-SLIT was started 3–5 months before the pollen season for 85.3%. Treatment was discontinued before the start of the pollen season in 11.0% of patients overall, generally because of an adverse event (78.8% of discontinuations). The mean duration of treatment was 5.2 months in adults and 5.6 months in children. At the end of follow-up, symptoms during the pollen season were intermittent for 75.0% of adults and 85.7% of children, and severity was mild for 61.8 and 66.0% respectively. During 5GPE-SLIT, the following symptoms reported during the previous year were not reported again in > 50% of patients: nasal congestion, rhinorrhoea, repeated sneezing, conjunctivitis and nasal pruritus. Conclusions: 5GPE-SLIT use was generally consistent with prescribing recommendations and was associated with an improvement of AR severity, with resolution of the principal AR symptoms in around half the patients treated. Trial registration EUPAS9358. Registered 13 May 2015. Not prospectively registered. http://www.encepp.eu/encepp/viewResource.htm?id=16229 [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
38. Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study.
- Author
-
Smith, Denis, Terrebonne, Eric, Rouyer, Magali, Blanc, Jean‐Frédéric, Breilh, Dominique, Pedeboscq, Stéphane, Le Monies, Alise, Lecomte, Coralie, Lassalle, Régis, Moore, Nicholas, and Fourrier‐Réglat, Annie
- Subjects
- *
COLON cancer treatment , *COHORT analysis , *PATIENTS , *METASTASIS , *MONOCLONAL antibodies - Abstract
Introduction of new agents for the treatment for colorectal cancer (CRC) has been accompanied by the publication of guidelines. The COLCHIC cohort was set up to evaluate CRC treatment practices and the use of these innovative and expensive agents. Patients initiating CRC treatment at the Bordeaux teaching hospital between 1 March 2005 and 1 March 2006 were identified, and treatment courses from 1 March 2005 to 31 December 2006 were studied; 192 patients were included, 188 with analysable data: 43 patients initiated 51 courses for non-metastatic cancer, 153 initiated 366 courses for metastatic cancer, eight patients initiated courses for both non-metastatic and metastatic cancer. Most treatments were used for indications found in guidelines published during the study (83.9%). Of the others, nearly half were approved in guidelines published subsequently. In this teaching hospital, prescribing practice was generally in line with recommendations, with an anticipation of future guidelines. This mostly concerned monoclonal antibodies, which were new at the time of the study. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.